Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

NCT05766267 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT05766267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05766267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 21, 2023
Completion date
December 31, 2027
Enrollment
288 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis infection, tuberculosis, pulmonary